However, the combination of DCAF7 knockdown with cisplatin markedly enhanced the tumor growth inhibition, achieving a TGI of 74.63% (P < 0.001) in NPC in vivo at the termination of the experiment (Figure 2B). The gene discussed is DCAF7; the disease is neoplasm.